Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol

BMC Cancer

Shaojun Zhu¹  Jeremie Calais²  Johannes Czernin²  Matthias Eiber³  Ken Herrmann⁴  Wolfgang P. Fendler⁴  Nader Hirmas⁴  Martin Stuschke⁵  Boris Hadaschik⁶  David Elashoff⁷  Nicholas G. Nickols⁸  Amar U. Kishan⁹ 

[1] Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Peter Norton Medical Building, 200 Medical Plaza, Suite B-114-51, 90095-7370, Los Angeles, CA, USA;Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Peter Norton Medical Building, 200 Medical Plaza, Suite B-114-51, 90095-7370, Los Angeles, CA, USA;Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA;Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA;Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany;Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstraße 55, 45131, Essen, Germany;Department of Radiotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany;Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA;Department of Medicine Statistics Core (DOMStat), UCLA CTSI Biostatistics and Computational Biology, University of California, Los Angeles, USA;Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA;Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, USA;Department of Radiation Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA;Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, USA;Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA;Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA;Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, USA;

关键词: Prostate cancer;    PSMA;    PET/CT;    Randomized phase 3 trial;    Definitive radiation therapy;   

DOI  :  10.1186/s12885-021-08026-w

来源: Springer

【 授权许可】

CC BY